Mastodon

Framycetin (Spray) Instructions for Use

ATC Code

R01AX08 (Framycetin)

Active Substance

Framycetin (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Antibacterial drug for topical use in ENT practice

Pharmacotherapeutic Group

Drugs for the treatment of nasal diseases; decongestants and other preparations for topical use; other drugs for the treatment of nasal diseases

Pharmacological Action

An antibiotic from the aminoglycoside group with a broad spectrum of action for topical use in otorhinolaryngology.

It acts bactericidally, damages the cytoplasmic membrane, disrupts the flow of metabolites inside the cell and causes rapid death of microorganisms.

It is active against most Gram-positive and Gram-negative bacteria: Staphylococcus aureus, Staphylococcus spp. (including strains resistant to other antibiotics), some strains of Streptococcus spp., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., Haemophilus influenzae, Salmonella spp., Shigella spp., Enterobacter spp., Proteus spp., Serratia marcescens, Pasteurella spp., Vibrio spp., Borrelia, Leptospira spp., Mycobacterium tuberculosis (including strains resistant to streptomycin), which cause the development of infectious processes in the upper respiratory tract.

Treponema spp., some strains of Streptococcus spp., and anaerobic microorganisms are resistant to framycetin.

Pharmacokinetics

When applied topically, it has low systemic absorption.

Indications

As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including: rhinitis, rhinopharyngitis, sinusitis (in the absence of septal damage).

Prevention and treatment of inflammatory processes after surgical interventions.

ICD codes

ICD-10 code Indication
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
Z29.2 Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)
ICD-11 code Indication
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
QC05.Y Other specified prophylactic measures

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer the spray intranasally only. Use 3 to 6 times per day.

Deliver one spray into each nostril per administration.

Before initial use, prime the pump by pressing the actuator several times until a full spray is produced.

Clear the nasal passages prior to application. Tilt the head slightly forward while using the spray.

Do not exceed the recommended frequency or duration of application.

The maximum treatment duration is 7 days. Discontinue use after one week.

Prolonged use beyond 7 days increases the risk of developing superinfection with non-susceptible organisms.

If no clinical improvement is observed within 3-4 days, re-evaluate the diagnosis and treatment strategy.

This regimen is for topical use only. Do not ingest or introduce into the eyes.

After use, wipe the spray tip with a clean tissue and replace the protective cap.

Adverse Reactions

Possible: allergic reactions.

Contraindications

Hypersensitivity to antibiotics of the aminoglycoside group; pregnancy, breastfeeding period.

Framycetin should not be used for washing the paranasal sinuses.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Pediatric Use

Can be used in children according to indications, in recommended doses.

Special Precautions

During treatment, the appearance of resistant strains of microorganisms is possible.

Aminoglycoside antibiotics can cause reversible, partial or complete deafness and have a nephrotoxic effect when used systemically and when applied topically to open wounds or damaged skin.

These effects are dose-dependent and are enhanced in cases of impaired liver or kidney function.

The risk of their occurrence should be taken into account in case of topical application of high doses of the drug in children.

Therapy should not be continued after the symptoms disappear.

Framycetin should not be used simultaneously with other antibiotics that have ototoxic and nephrotoxic effects (streptomycin, monomycin, kanamycin, gentamicin).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

West, LLC (Russia)

Manufactured By

Samaramedprom, OJSC (Russia)

Dosage Form

Bottle Rx Icon Framycetin Nasal spray 1.25%

Dosage Form, Packaging, and Composition

Nasal spray

Framycetin 1.25%

10 ml – bottles – for hospitals
10 ml – bottles – cardboard packs – By prescription
15 ml – bottles – for hospitals
15 ml – bottles – cardboard packs – By prescription
20 ml – bottles – for hospitals
20 ml – bottles – cardboard packs – By prescription
25 ml – bottles – for hospitals
25 ml – bottles – cardboard packs – By prescription

Marketing Authorization Holder

Vita Line, LLC (Russia)

Manufactured By

Pharmtekhnologiya LLC (Republic of Belarus)

Dosage Form

Bottle Rx Icon Framycetin Nasal spray 12.5 mg/1 mL: 15 mL bottle

Dosage Form, Packaging, and Composition

Nasal spray in the form of a transparent or slightly opalescent, colorless or yellowish solution.

1 ml
Framycetin sulfate 12.5 mg (8000 IU)

Excipients : sodium chloride, sodium citrate, methylparahydroxybenzoate (E218), citric acid monohydrate, purified water.

15 ml – polyethylene bottles (1) with a nasal spray nozzle – cardboard packs.

Marketing Authorization Holder

Formula-FR, LLC (Russia)

Manufactured By

YUGPHARM, LLC (Russia)

Dosage Form

Bottle Rx Icon Framycetin Nasal spray 1.25%

Dosage Form, Packaging, and Composition

Nasal spray

1 ml
Framycetin sulfate 12.5 mg

15 ml – bottles – cardboard packs – By prescription

Marketing Authorization Holder

Morelor LLC (Russia)

Manufactured By

YUGPHARM, LLC (Russia)

Dosage Form

Bottle Rx Icon Framycetin Morelor® Nasal spray 1.25%

Dosage Form, Packaging, and Composition

Nasal spray

1 ml
Framycetin sulfate 12.5 mg

15 ml – bottles – cardboard packs – By prescription

Marketing Authorization Holder

Pharmtekhnologiya LLC (Republic of Belarus)

Dosage Form

Bottle Rx Icon Framycetin PhT Nasal spray 1.25%: 10 mL or 15 mL bottle

Dosage Form, Packaging, and Composition

Nasal spray in the form of a transparent or slightly opalescent, colorless or yellowish solution.

1 ml
Framycetin sulfate 12.5 mg (8000 IU)

Excipients : sodium chloride, sodium citrate, methylparahydroxybenzoate (E218), citric acid monohydrate, purified water.

10 ml – polymer bottles (1) with a nasal spray nozzle – cardboard packs.
15 ml – polymer bottles (1) with a nasal spray nozzle – cardboard packs.

TABLE OF CONTENTS